Kyverna Therapeutics, Inc. (KYTX)
| Market Cap | 510.21M +217.1% |
| Revenue (ttm) | n/a |
| Net Income | -152.64M |
| EPS | -2.88 |
| Shares Out | 61.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 500,780 |
| Open | 8.26 |
| Previous Close | 8.35 |
| Day's Range | 8.20 - 8.38 |
| 52-Week Range | 3.55 - 13.67 |
| Beta | 1.99 |
| Analysts | Strong Buy |
| Price Target | 30.40 (+268.49%) |
| Earnings Date | Aug 11, 2026 |
About KYTX
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreemen... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for KYTX stock is "Strong Buy." The 12-month stock price target is $30.4, which is an increase of 268.49% from the latest price.
News
Kyverna Therapeutics to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologi...
Kyverna Therapeutics reports Q2 EPS (63c), consensus (68c)
“Kyverna continues to advance our rolling BLA submission for stiff person syndrome, progress commercial launch readiness activities and accelerate enrollment in our registrational trial in generalized...
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy's potential across neuroimmunol...
Kyverna Therapeutics Earnings release: Q2 2026
Kyverna Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Kyverna Therapeutics Quarterly report: Q2 2026
Kyverna Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Kyverna Therapeutics Slides: Corporate presentation
Kyverna Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Kyverna Therapeutics, ElevateBio announce miv-cel manufacturing agreement
Kyverna Therapeutics (KYTX) and ElevateBio announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel, Kyverna’s autologous CD19-directed CAR T-cell therapy. Th...
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
EMERYVILLE, Calif., and WALTHAM, Mass.
Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer
Kyverna Therapeutics (KYTX) announced the appointment of Ritesh Srivastava as chief legal and compliance officer, effective June 22. Srivastava brings extensive experience spanning legal, corporate st...
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
EMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune ...
Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Pioneering autologous CAR T therapies, the company reported strong clinical results in SPS and MG, with no high-grade adverse events and significant functional improvements. FDA alignment and scalable manufacturing support a Q4 BLA submission and targeted commercial launch.
Kyverna Therapeutics presents updated COMPARE trial data at EULAR
Kyverna Therapeutics (KYTX) announced the presentation of updated data from the Phase 1 portion of COMPARE, a Phase 1/2 investigator-initiated trial evaluating miv-cel in patients with active anti-cit...
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36 Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset Miv-...
Kyverna Therapeutics Slides: Corporate presentation
Kyverna Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Kyverna Therapeutics Transcript: AGM 2026
The meeting highlighted a pivotal year marked by regulatory progress and commercial transition, with key director elections and auditor ratification approved. Strategic focus remains on launching mivocabtagene and expanding the neuroimmunology franchise.
Kyverna Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Miv-cel has shown transformative, durable results in SPS, with strong FDA alignment and high physician and payer enthusiasm. Launch preparations target 10 academic centers, with scalable manufacturing and expansion into MG, MS, and RA planned.
Kyverna Therapeutics CFO Marc Grasso to step down, Greg Martini to succeed
Kyverna Therapeutics (KYTX) announced the appointment of Greg Martini as CFO, effective May 18. Martini succeeds Marc Grasso who will be consulting for the company to ensure a transition. With…
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
Veteran biopharma leader joins to help lead Kyverna's next phase of commercial growth Veteran biopharma leader joins to help lead Kyverna's next phase of commercial growth
Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Kyverna Therapeutics (KYTX) to $25 from $20 and keeps a Buy rating on the shares. Following a discussion with…
Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan
JPMorgan analyst Brian Cheng lowered the firm’s price target on Kyverna Therapeutics (KYTX) to $29 from $30 and keeps an Overweight rating on the shares. The firm updated the company’s…
Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)
Kyverna reported a net loss of $39.7M for the first quarter ended March 31. Research and development expenses were $30.1M, while general and administrative expenses were $11.3M for the period.
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated
Kyverna Therapeutics Earnings release: Q1 2026
Kyverna Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Kyverna Therapeutics Quarterly report: Q1 2026
Kyverna Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Kyverna Therapeutics Slides: Investor presentation
Kyverna Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.